All-cause mortality in patients with chronic obstructive pulmonary disease is improved by a high level of continuity of care.
A high level of continuity of care (COC) improves all-cause mortality in patients with chronic obstructive pulmonary disease (COPD), according to a Korean study of 3090 COPD patients in a nationwide health insurance claims database. The study was published in PLOS One.
Kyong Hee Cho, MD, of the Department of Public Health, Graduate School, Yonsei University, Seoul, South Korea, and colleagues conducted a longitudinal, population-based retrospective cohort study in adult patients with COPD from 2002 to 2012. The sample included patients ages 40 years and older who developed COPD in 2005 and survived until 2006. The main goal of the study was to measure COC over 7 years in patients with COPD and to investigate the association between COC and all causes of mortality. In addition, the study sought to identify other mortality-related factors in COPD patients.
The investigators defined continuity as longitudinal continuity. They calculated the COC index in subjects with 4 or more ambulatory care visits per year to reflect the distribution of visits to different healthcare institutions. It is influenced by both the total number of providers and the total number of visits. The index ranges from 0 to 1; a higher value corresponds to better COC.
A total of 60.8% of participants died prior to the end of the study. There was a statistically significant difference in adjusted median years of survival when home oxygen therapy was used (P = 0.04). In addition, unadjusted and adjusted median years of survival decreased as the number of hospital admissions increased. Median years of survival for individuals with high COC (COC index ≥0.75) was 3.92; median years of survival for patients with low COC (COC index <0.75) was 2.58.
Low COC was associated with a 22% increased risk of all-cause mortality. Not receiving oxygen therapy at home was associated with a 23% increased risk of all-cause mortality. The risk of all-cause mortality for patients admitted one time increased 38%, admitted two times was 63%, and admitted three or more times was 96% compared to the group with no admissions.
The researchers concluded that high COC was associated with a decreased risk of all-cause mortality and that home oxygen therapy and number of hospital admissions may predict mortality in patients with COPD. They noted that further research on the associations between COC and various healthcare outcomes, adjusting for potential confounders such as income, education, and health behaviors, is needed.
Interstitial Lung Abnormalities in Patients With COPD Linked to Cancer, Heart Failure Risks
October 23rd 2024Interstitial lung abnormalities (ILAs) in patients with chronic obstructive pulmonary disease (COPD) are linked to lower lung adenocarcinoma rates but higher rates of other cancers and heart failure.
Read More
Insurance Insights: Dr Jason Shafrin Estimates DMD Insurance Value
July 18th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the July 2024 issue of The American Journal of Managed Care® that estimates the insurance value of novel Duchenne muscular dystrophy (DMD) treatment.
Listen
FIT Completion, Yield Rates in CRC Screening Similar After New Screening Guidelines
October 22nd 2024Patients were found to have similar completion and yield rates for the fecal immunochemical test (FIT) at both 45 years and 50 years, making screening for colorectal cancer (CRC) effective in younger patients.
Read More
From Polypharmacy to Personalized Care: Dr Nihar Desai Discusses Holistic Cardiovascular Care
May 30th 2024In this episode of Managed Care Cast, Nihar Desai, MD, MPH, cardiologist and vice chief of Cardiology at the Yale School of Medicine, discusses therapies for cardiovascular conditions as they relate to patient adherence, polypharmacy, and health access.
Listen
The Latest in New and Emerging Therapies in Schizophrenia: Dr Megan Ehret
October 22nd 2024In addition to Cobenfy being approved for schizophrenia, there are other drugs with novel mechanisms being studied that may mean combination therapies or, at least, more options for patients in the future.
Read More
Delayed Diagnoses, Oxygen Therapy Use Linked to Worse Outcomes in Patients With Fibrotic ILD
October 21st 2024Posters presented at the CHEST 2024 annual meeting revealed that delays in diagnosing fibrotic interstitial lung disease (ILD) can negatively impact overall survival, while supplemental oxygen therapy may exacerbate clinical burdens through increased rates of acute exacerbations and hospitalizations.
Read More